FGCL-3019-095 Pro00108483 Zephyrus II: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects with Idiopathic Pulmonary Fibrosis (IPF)

Administered By

Awarded By

Contributors

Start/End

  • June 23, 2022 - March 31, 2026